Kaleido Biosciences said on March 24 the company’s experimental oral treatment cut recovery time as well as hospitalizations and emergency room visits in patients with mild to moderate Covid-19, in an early trial.

Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed. 

The COVID-19 global pandemic, overcrowding of hospitals, the highly contagious virus affecting healthcare professionals and unrelated illnesses has led to a more than 1,000 percent increase of telemed application downloads and memberships. Is this a paradigm shift?